BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kolly P, Dufour J. A strong message is needed to address the issue of HCC recurrence after DAA therapy. Journal of Hepatology 2016;65:1268-9. [DOI: 10.1016/j.jhep.2016.07.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Russo FP, Bruno S, Farinati F. HCV clearance by direct antiviral therapy and occurrence/recurrence of hepatocellular carcinoma: A “true-or-false game”. Digestive and Liver Disease 2017;49:321-5. [DOI: 10.1016/j.dld.2017.01.159] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
2 Kolly P, Waidmann O, Vermehren J, Moreno C, Vögeli I, Berg T, Semela D, Zeuzem S, Dufour JF. Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. J Hepatol 2017;67:876-8. [PMID: 28733219 DOI: 10.1016/j.jhep.2017.07.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
3 Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavò MR, Madonia S, Distefano M, Larocca L, Prestileo T, Tinè F, Bertino G, Giannitrapani L, Benanti F, Licata A, Scalisi I, Mazzola G, Cartabellotta F, Alessi N, Barbàra M, Russello M, Scifo G, Squadrito G, Raimondo G, Craxì A, Di Marco V, Cammà C; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV). Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther 2017;46:688-95. [DOI: 10.1111/apt.14256] [Cited by in Crossref: 92] [Cited by in F6Publishing: 85] [Article Influence: 18.4] [Reference Citation Analysis]
4 Ramadori G, Bosio P, Moriconi F, Malik IA. Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy. BMC Cancer 2018;18:257. [PMID: 29510685 DOI: 10.1186/s12885-018-4175-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
5 Shen Z, Li B, Liu Y, Zheng G, Guo Y, Zhao R, Jiang K, Fan L, Shao J. A self-assembly nanodrug delivery system based on amphiphilic low generations of PAMAM dendrimers-ursolic acid conjugate modified by lactobionic acid for HCC targeting therapy. Nanomedicine 2018;14:227-36. [PMID: 29128661 DOI: 10.1016/j.nano.2017.10.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
6 Jain A, Miller D, Schreibman I, Riley TR 3rd, Krok KL, Dohi T, Sharma R, Kadry Z. Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy? Hepatol Int 2019;13:190-8. [PMID: 30680672 DOI: 10.1007/s12072-019-09930-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]